Steven Ades is an Oncology physician affiliated with University of Vermont. OpenAlex indexes 76 publications with 2,203 citations (h-index 18); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
111 Colchester Ave
Hematology/oncology, Acc Level 2
Burlington, VT 054011473
Telephone
802-847-8400Registry record last updated 22 Aug 2007.
Clinical trials
- Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
Sponsor: University of Vermont
- Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
Sponsor: University of Vermont
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
31.7%Corticosteroid20.9%Prednisone100%Part D≥34 patientsSerotonin-3 Receptor Antagonist3.7%Ondansetron Odt100%Part D≥18 patients+ 3 more classes in this area
Cancer & immunology
30.4%Cytochrome P450 17A1 Inhibitor15.3%Abiraterone Acetate100%Part D≥21 patientsKinase inhibitor4.2%Cabometyx100%Part D<11 patients+ 3 more classes in this area
Nervous system
9.4%Phenothiazine4.2%Prochlorperazine Maleate100%Part D≥18 patientsAtypical Antipsychotic2.7%Olanzapine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology
2024 - Venous thromboembolism prevention program implementation in a community oncology practice: a cohort study
The Lancet Regional Health - Americas
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David Krag, MD
University of Vermont
David Schneider, MD
University of Vermont
Robert Althoff, MD, PhD
University of Vermont
John Helzer, MD
University of Vermont
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”